Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Thursday after the company announced it received regulatory authorization from Brazil’s ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial for INO-4800. The stock looks to be nearing resistance in what technical traders call an ascending triangle pattern. The stock is trading above the 50-day moving average (green), but below the 200-day moving average (blue) Thursday, indicating the stock is likely in a period of consolidation.